Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3 ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.

MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a ...

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced its financial results for the fourth quarter and ...

MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect MiNK Therapeutics to post earnings of ($0.

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. Dylan Berman Why Byrna Technologies ...

Subscribers can access 8 additional key ProTips about INKT's financial position. The stockholder's vote yielded 26,500,274 votes in favor, 1,026,255 against, and 56,013 abstentions, with no broker ...

“These latest data demonstrate the remarkable potential of combining BOT/BAL with a novel iNKT cell therapy to broaden and intensify immune responses against resistant gastric tumors,” said Dr ...